IIPR Earnings Preview

Piper raises target to $45, keeps Underweight — stabilization, not transformation

The $1 target bump despite north of $200 million in AFFO signals that Piper is pricing IIPR as an income play with ceiling, not a recovery story. Better execution on tenant backfills and life science momentum could narrow the gap between current price and $45, but won't ignite the kind of rerating that would flip the Underweight call. This is a test of management's ability to stabilize without proving they can grow through the cannabis headwind.

Watch: Q1 2026 backfill execution at PharmaCann, 4Front, and Gold Flora, plus life science leasing velocity outside Boston. Material tenant writedowns or delayed backfill would confirm Piper's thesis; clean execution without credit events could pressure the Underweight rating lower.